Skip to content
OpenCapital
Get started

EXOZ EXOZ Licensed Product — Payments To Acquire Licensed Product

Similar metrics at other companies

OrthoPediatrics logo
KIDSPayments To Acquire Private Companies And Licenses
$504.25K+212%
BH
BHBrand licensing — CapEx
$444K—
CHE
CHEPayments to Acquire Productive Assets
$37.86M+175%
OS Therapies logo
OSTXPayments to Acquire Productive Assets
$316.42K—
Identive logo
INVEPayments to Acquire Productive Assets
$882K+193%
The Manitowoc Company logo
MTWPayments To Acquire Other Productive Assets
$0-100%

Other financials

Income statement

See full
Revenue$17.5K—
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-3.3%
Enterprise value$76.57M+3.5%
P/S1,096.1×—

Profitability

See full
Operating margin-14,489.6%—
Net margin-2,909.1%—
FCF margin-10,117.8%—

Returns & leverage

See full
Return on equity-185.8%—
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept EXOZ:PaymentsToAcquireLicensedProduct.

The official record: EXOZ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's licensed product — payments to acquire licensed product.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's licensed product — payments to acquire licensed product?
EXOZ (EXOZ) reported licensed product — payments to acquire licensed product of $250K in Q1 2026.
How has EXOZ's licensed product — payments to acquire licensed product changed year-over-year?
EXOZ's licensed product — payments to acquire licensed product decreased by 0.0% year-over-year, from $250K to $250K.
What does licensed product — payments to acquire licensed product mean?
This metric represents the total cash outflows or capital expenditures dedicated to the acquisition, licensing, or procurement of intellectual property and product rights for a specific business segment. It reflects the company's investment strategy in securing external technologies or product portfolios to bolster its internal manufacturing or commercial capabilities. Monitoring this figure helps investors assess the cost of inorganic growth and the ongoing financial commitment required to maintain or expand the product pipeline.